Clinical Commentary: The Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer
February 7th 2023During a Targeted Oncology case-based roundtable event, Nancy Dawson, MD, discussed the treatment of patients with metastatic hormone-sensitive prostate cancer and what important aspects of treatment clinicians should home in on.
Physicians Discuss Their Impressions of Recent IO/TKI Trials for HCC
February 6th 2023During a Targeted Oncology case-based roundtable event, Amit Singal, MD, and participants discussed the significance of LEAP-002 and other trials investigating immunotherapy plus tyrosine kinase inhibitor therapy in patients with hepatocellular carcinoma.
Managing Frontline Toxicities in Patients With RCC
February 1st 2023During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed with participants their experiences managing toxicities of frontline combination therapy for renal cell carcinoma. This is the second of 2 articles based on this event.
TOPAZ-1 Data Support New Frontline Option in Patients With BTC
January 30th 2023During a Targeted Oncology case-based roundtable event, Nilofer S. Azad, MD, discussed the data supporting the previous standard of care and the new frontline regimen of gemcitabine, cisplatin, and durvalumab for patients with biliary tract cancers.
Physicians Discuss Potential of Frontline Triplet Regimens for RCC
January 27th 2023During a Targeted Oncology case-based roundtable event, Alan Tan, MD, discussed with participants their experience with tyrosine kinase inhibitor/immunotherapy combinations and the most recent results of triplet trials.
The Importance of Molecular Testing Before Adjuvant Therapy for NSCLC
January 24th 2023During a Targeted Oncology case-based roundtable event, Edward S. Kim, MD, MBA, discussed adjuvant therapy options and the use of molecular testing in patients with earlier-stage non–small cell lung cancer. This is the first of 2 articles based on this event.
Long-Term Follow-Up Shows Olaparib’s Efficacy in Ovarian Cancer
January 20th 2023During a Targeted Oncology case-based roundtable event, Paul D. DiSilvestro, MD, discussed the long-term results from the SOLO-1 trial of olaparib maintenance for patients with ovarian cancer. This is the first of 3 articles based on this event.
Piotrowska Looks at Amivantamab and Mobocertinib for Patients With Rare Driver Mutations in NSCLC
January 16th 2023During a Targeted Oncology case-based roundtable event, Zofia Piotrowska, MD, MHS, discussed molecular testing for actionable mutations and recommended treatments for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.
Roundtable Discussion: Komrokji Evaluates Pathology, Risk Assessment, and Therapy for Myelofibrosis
January 14th 2023During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed with participants their approach toward assessing and treating a patient with symptoms possibly indicating primary myelofibrosis.
Callander Compares Doublet and Triplet Therapy in Early-Relapse Multiple Myeloma
January 13th 2023During a Targeted Oncology case-based roundtable event, Natalie S. Callander, MD, discussed studies that support alternative combination regimens after early relapse on bortezomib, lenalidomide, and dexamethasone for multiple myeloma.
Roundtable Discussion: Moon Discusses Best Path for Maintenance Care in Advanced Bladder Cancer
January 13th 2023During a Targeted Oncology case-based roundtable event, Helen Moon, MD, discussed with participants their approaches to metastatic bladder cancer and immunotherapy in the switch maintenance setting.
Brose and Laetsch Discuss Rare Actionable Targets in Patients With Thyroid Cancer
January 12th 2023During a Targeted Oncology case-based roundtable event, Marcia S. Brose, MD, PhD, and Theodore W. Laetsch, MD, discussed the data supporting the use of NTRK inhibitors in a patient with metastatic papillary thyroid cancer.
IO/IO Versus IO/TKI Frontline Therapy for Intermediate-Risk RCC
January 11th 2023During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed the factors influencing the choice of frontline therapy for a patient with stage IV clear cell renal cell carcinoma whose risk status was intermediate.
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
January 6th 2023During a Targeted Oncology case-based roundtable event, Christopher R. Flowers, MD, MS, discussed the choice of bridging therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who may receive CAR (chimeric antigen receptor) T-cell therapy. This is the second of 2 articles based on this event.
Ruxolitinib’s Role for Symptoms and Survival Benefit in Myelofibrosis
January 4th 2023During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed data supporting the use of ruxolitinib and what role it may play in improving long-term outcomes for patients with myelofibrosis. This is the second of 2 articles based on this event.
Real-World Experience With Referral and Access to CAR T-Cell Therapy
December 30th 2022During a Targeted Oncology case-based roundtable event, Christopher R. Flowers, MD, MS, discussed with participants their experiences referring patients for chimeric antigen receptor T-cell therapy and using bridging therapy. This is the first of 2 articles based on this event.
Roundtable Discussion: Treatment Goals for HCC and Tolerability of Frontline Regimens
December 27th 2022During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the case of a patient with a 4.5-cm Liver Imaging Reporting and Data System category 5 (LR-5) hepatic mass, Crohn disease, and cirrhosis.
Second-Line Considerations After Immune Toxicity From Prior RCC Therapy
December 21st 2022During a Targeted Oncology case-based roundtable event, Saby George, MD, discussed which second-line therapy would be appropriate for a patient who discontinued frontline immunotherapy/tyrosine kinase inhibitor therapy due to immune-related toxicity.